NeuroPace, Inc. (NASDAQ:NPCE) Shares Sold by Nantahala Capital Management LLC

Nantahala Capital Management LLC trimmed its position in NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 7.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 562,073 shares of the company's stock after selling 45,817 shares during the quarter. Nantahala Capital Management LLC owned 1.88% of NeuroPace worth $6,290,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. State Street Corp increased its stake in shares of NeuroPace by 9.1% in the third quarter. State Street Corp now owns 155,490 shares of the company's stock valued at $1,084,000 after buying an additional 12,912 shares during the period. Barclays PLC increased its holdings in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company's stock valued at $144,000 after acquiring an additional 16,007 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of NeuroPace by 8.7% during the third quarter. Geode Capital Management LLC now owns 317,192 shares of the company's stock valued at $2,211,000 after buying an additional 25,330 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company's stock valued at $84,000 after buying an additional 6,181 shares during the last quarter. Finally, KCK LTD. purchased a new position in shares of NeuroPace during the fourth quarter valued at approximately $58,981,000. Institutional investors own 78.83% of the company's stock.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Wells Fargo & Company upped their price target on NeuroPace from $13.00 to $17.00 and gave the company an "overweight" rating in a research report on Thursday, January 30th. Cantor Fitzgerald lifted their price target on shares of NeuroPace from $19.00 to $20.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, UBS Group started coverage on shares of NeuroPace in a report on Tuesday, January 21st. They issued a "buy" rating and a $17.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $15.20.

Insider Transactions at NeuroPace

In other news, major shareholder Ltd. Kck sold 5,270,845 shares of the firm's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total value of $49,545,943.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Martha Morrell sold 78,334 shares of NeuroPace stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $13.72, for a total value of $1,074,742.48. Following the sale, the insider now directly owns 81,993 shares of the company's stock, valued at approximately $1,124,943.96. This represents a 48.86 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 22.20% of the company's stock.

NeuroPace Price Performance

Shares of NPCE stock traded up $0.10 on Thursday, hitting $11.79. 100,405 shares of the stock traded hands, compared to its average volume of 130,971. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77. The firm has a market cap of $386.16 million, a price-to-earnings ratio of -11.79 and a beta of 2.03. The firm has a 50 day simple moving average of $11.64 and a two-hundred day simple moving average of $10.97. NeuroPace, Inc. has a 52 week low of $5.45 and a 52 week high of $15.11.

NeuroPace (NASDAQ:NPCE - Get Free Report) last issued its quarterly earnings data on Tuesday, March 4th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The business had revenue of $21.47 million during the quarter, compared to analysts' expectations of $21.14 million. As a group, equities research analysts predict that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

NeuroPace Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.